Latest News

Second pig heart recipient dies


 

Lawrence Faucette, the 58-year-old man with terminal heart disease who received the world’s second genetically modified pig heart transplant, died on Oct. 30, 2023, the University of Maryland Medical Center (UMMC), Baltimore, reported in a statement.

Mr. Faucette, a former lab tech who was turned down repeatedly for a standard allograft transplantation because of his various medical conditions, received the pig heart transplant on Sept. 20, 2023.

He first came to UMMC as a patient on Sept. 14. When he was admitted, he was in end-stage heart failure. Shortly before the surgery, his heart stopped, and he required resuscitation.

On Sept. 15, the Food and Drug Administration granted an emergency authorization for the surgery through its single-patient investigational new drug compassionate use pathway.

“My only real hope left is to go with the pig heart, the xenotransplant,” Mr. Faucette said in an interview from his hospital room a few days before his surgery. “At least now I have hope, and I have a chance.” He made “significant progress” in the month after the surgery, participating in physical therapy and spending time with family, according to the university. But in the days before his death, the heart showed signs of rejection.

“Mr. Faucette’s last wish was for us to make the most of what we have learned from our experience, so others may be guaranteed a chance for a new heart when a human organ is unavailable,” said Bartley P. Griffith, MD, who transplanted the pig heart into Mr. Faucette at UMMC. “He then told the team of doctors and nurses who gathered around him that he loved us. We will miss him tremendously.”

Muhammad M. Mohiuddin, MD, professor of surgery and scientific/program director of the Cardiac Xenotransplantation Program at the University of Maryland School of Medicine, said that “Mr. Faucette was a scientist who not only read and interpreted his own biopsies, but who understood the important contribution he was making in advancing the field.

“As with the first patient, David Bennett Sr., we intend to conduct an extensive analysis to identify factors that can be prevented in future transplants; this will allow us to continue to move forward and educate our colleagues in the field on our experience,” Dr. Mohiuddin added.

The researchers don’t plan to make further comments until their investigation is complete, a university spokesperson said in an interview.

UMMC performed the first transplant of a genetically modified pig heart in January 2022. Mr. Bennett, the recipient of that heart, survived for 60 days. The researchers published their initial findings in The New England Journal of Medicine, and then the results of their follow-up investigation in The Lancet.

A version of this article first appeared on Medscape.com.

Recommended Reading

Does new heart transplant method challenge definition of death?
MDedge Internal Medicine
New update on left atrial appendage closure recommendations
MDedge Internal Medicine
High salt intake linked to atherosclerosis even with normal BP
MDedge Internal Medicine
Spherical heart may predict cardiomyopathy, AFib
MDedge Internal Medicine
AHA statement targets nuance in CVD risk assessment of women
MDedge Internal Medicine
Marijuana linked to higher PAD risk
MDedge Internal Medicine
Circulatory support for RV failure caused by pulmonary embolism
MDedge Internal Medicine
TAVI turmoil: Did an ANP perform transcatheter aortic valve replacement in the U.K.?
MDedge Internal Medicine
Aspirin not the best antiplatelet for CAD secondary prevention in meta-analysis
MDedge Internal Medicine
AHA/ACC issue updated chronic coronary disease guidelines
MDedge Internal Medicine